- JNJ -0.31% ITCI
Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Boring Dividend Stocks to Buy.
JNJ to Acquire Halda Therapeutics for $3.05 Billion to Boost Oncology Pipeline On November 18, Johnson & Johnson (NYSE:JNJ) revealed that it plans to acquire privately held Halda Therapeutics for $3.05 billion in cash, a move intended to strengthen its position in therapies focused on solid tumors and prostate cancer. The purchase represents J&J’s second sizable transaction of the year, following its $14.6 billion takeover of Intra-Cellular Therapies in January, as the company continues shifting toward faster-growing areas of healthcare while managing the impact of losing exclusivity on Stelara, its top-selling immune disease drug.
Halda’s pipeline is led by HLD-0915, a prostate cancer therapy currently in early-to mid-stage clinical development. The company is also advancing several other experimental candidates targeting breast, lung, and various other tumor types.
In the previous month, Johnson & Johnson (NYSE:JNJ) reported third-quarter revenue of $15.56 billion from its Innovative Medicine division, which includes oncology. That result topped analysts’ expectations of $15.42 billion, based on LSEG data.
Johnson & Johnson (NYSE:JNJ) is a global healthcare company engaged in researching, developing, and producing a broad range of pharmaceuticals and medical technologies.
While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Best Long Term Stocks to Buy According to Reddit and 15 Best Stocks to Buy for Medium Term
Disclosure: None.
Terms and Privacy Policy Privacy Dashboard More Info